Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Is cancer immunotherapy a private affair?: Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“The model achieved AUCs of 0.734, 0.729, and 0.935 at 1, 2, and 3 years, respectively (Fig. 4F).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“Cox proportional hazard regression analysis established the algorithm’s independence as a prognostic determinant following adjustment for conventional clinicopathological covariates (P < 0.001; Fig. 4G and table S1).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“it achieved an AUC of 0.989, an AUPRC of 0.993, an F1 score of 0.99, and a C-index of 0.989 (Fig. 4, A and B, and fig. S2A).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“To stratify our cohort, “clinical benefit” was defined using a composite end point of complete response or partial response to ipilimumab by RECIST criteria (21) or stable disease by RECIST criteria with overall survival greater than 1 year (n = 27).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“We performed somatic mutation identification (table S1) and germline human lymphocyte antigen (HLA) typing (table S2) using established methods (14, 19).”
Self-citationThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Incorporation of patient-matched RNA-level information may help prioritize putative neoantigens and elucidate possible tumor immune microenvironmental effects, including interferon-related genes and additional immune checkpoint molecules that are relevant in melanoma (28).”
Cited by
Items 601–700 of 1,010
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 83
Enabling Precision Oncology Through Precision Diagnostics
Brown, N. A., & Elenitoba‐Johnson, K. S. J. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012735 · Cited by 93
Inhibition of UBA6 by inosine augments tumour immunogenicity and responses
(2022) · doi:10.1038/s41467-022-33116-z · Cited by 82
Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Quandt, D., Zucht, H. D., Amann, A., Wulf-Goldenberg, A., Borrebaeck, C. A. K., Cannarile, M. A., Lambrechts, D., Oberacher, H., Garrett, J., Nayak, T. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17397 · Cited by 88
Kim, H. S., Lee, J. H., Nam, S. J., Ock, C., Moon, J.-W., Yoo, C. W., Lee, G. K., & Han, J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.008 · Cited by 87
Bertucci, F., Finetti, P., Simeone, I., Hendrickx, W., Wang, E., Marincola, F. M., Viens, P., Mamessier, É., Ceccarelli, M., Birnbaum, D., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0309-1 · Cited by 89
Liu, C. J., Schaettler, M. O., Blaha, D. T., Bowman-Kirigin, J. A., Kobayashi, D. K., Livingstone, A. J., Bender, D. E., Miller, C. A., Kranz, D. M., Johanns, T. M., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa050 · Cited by 90
PIEZO1 mechanically regulates the antitumour cytotoxicity of T lymphocytes
Pang, R., Sun, W., Yang, Y., Wen, D., Lin, F., Wang, D., Li, K., Zhang, N., Liang, J., Xiong, C., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01188-5 · Cited by 97
“Insufficient CD8 + Tcell tumour infiltration is one of the key underlying factors for the tumour evasion of ICB immunotherapy 33 .”
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Bhandarkar, V., Dinter, T., & Spranger, S. (2025) · Science Immunology · doi:10.1126/sciimmunol.adf4726 · Cited by 96
Lack of detectable neoantigen depletion signals in the untreated cancer genome
Van den Eynden, J., Jiménez-Sánchez, A., Miller, M. L., & Larsson, E. (2019) · Nature Genetics · doi:10.1038/s41588-019-0532-6 · Cited by 80
Jensen, C., Madsen, D. H., Hansen, M., Schmidt, H., Svane, I. M., Karsdal, M. A., & Willumsen, N. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0474-z · Cited by 79
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
Linette, G. P., & Carreno, B. M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00523-x · Cited by 89
Unraveling the Wide Spectrum of Melanoma Biomarkers
Revythis, A., Shah, S., Kutka, M., Moschetta, M., Öztürk, M. A., Pappas‐Gogos, G., Ioannidou, E., Sheriff, M., Rassy, E., & Boussios, S. (2021) · Diagnostics · doi:10.3390/diagnostics11081341 · Cited by 85
Wu, J., Zhu, Y., Luo, M., & Li, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748221 · Cited by 105
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 92
Byron, S. A., Tran, N. L., Halperin, R. F., Phillips, J. J., Kuhn, J. G., de Groot, J. F., Colman, H., Ligon, K. L., Wen, P. Y., Cloughesy, T. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0963 · Cited by 81
“There are several emerging reports in other tumor types that a high number of overall mutations or mutations in specific DNA repair genes may be associated with increased sensitivity to immune checkpoint inhibitors (50-53).”
BackgroundEmerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 81
“Melanoma is also the only cancer in which anti-CTLA-4 monotherapy produces a significant response rate, and correlations between mutational load and anti-CTLA-4 response in melanoma have been reported.(89,90) In contrast, tumors with relatively low median TMB, such as pancreatic and prostate cancer, have shown little…”
BackgroundPredictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer
Kou, F., Wu, L., Ren, X., & Yang, L. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.05.010 · Cited by 92
“Recent studies have reported that TMB alone is not a sensitive marker of the efficacy of immunotherapy.(17,18) In two independent cohorts of patients treated with immune checkpoint inhibitor (ICI) anti-CTLA4, Davoli et al.”
BackgroundCurrent Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Lü, Z., Peng, Z., Liu, C. X., Wang, Z., Wang, Y., Jiao, X., Li, J., & Shen, L. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100041 · Cited by 91
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity
Zhou, J., Tison, K., Zhou, H., Bai, L., Acharyya, R. K., McEachern, D., Metwally, H., Wang, Y., Pitter, M. R., Choi, J. E., et al. (2025) · Nature · doi:10.1038/s41586-025-09000-3 · Cited by 102
Neoantigen-based cancer immunotherapy
Bobisse, S., Foukas, P. G., Coukos, G., & Harari, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.17 · Cited by 85
“Along the same line, nonsynonymous mutational load, as well as a high frequency of neoAgs, were associated with clinical benefit in patients with metastatic melanoma treated with ipilimumab (anti-CTLA-4 blocking monoclonal antibody) (35).”
BackgroundPark, S. E., Park, K., Lee, E., Kim, J., Ahn, J. S., Im, Y., Lee, C., Jung, H., Cho, S. Y., Park, W., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466768 · Cited by 84
“cer patients with a high TMB, several immunotherapeutics that control immune check-points are still under exploration.(14)”
BackgroundImmune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
Harkus, U., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.005 · Cited by 79
Ning, B., Liu, Y., Wang, M., Li, Y., Xu, T., & Wei, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.748674 · Cited by 85
Chen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 94
Grandi, A., Tomasi, M., Zanella, I., Ganfini, L., Caproni, E., Fantappiè, L., Irene, C., Frattini, L., Isaac, S. J., König, E., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00253 · Cited by 77
Hao, D., Liu, J., Chen, M., Li, J., Wang, L., Li, X., Zhao, Q., & Di, L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3862 · Cited by 85
“A high density of TILs, as an indicator of in situ immune activity, is reported to be important in the setting of the immune-checkpoint blockade (8, 9).”
BackgroundBiomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 81
Quantitative Prediction of the Landscape of T Cell Epitope Immunogenicity in Sequence Space
Ogishi, M., & Yotsuyanagi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00827 · Cited by 96
Immune response drives outcomes in prostate cancer: implications for immunotherapy
Meng, J., Zhou, Y., Lu, X., Bian, Z., Chen, Y., Fan, S., Zhou, J., Zhang, L., 郝宗耀, Zhang, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12887 · Cited by 87
Zhang, C., Yin, K., Liu, S. M., Yan, L., Su, J., Wu, Y.-L. L. C., Zhang, X., Zhong, W., & Yang, X.-N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002312 · Cited by 88
Guo, J., Chen, D., Deng, S.-H., Huang, J.-R., Song, J., Li, X.-Y., Cui, B., & Liu, Y. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03076-2 · Cited by 85
Genomic characterization of high-risk non-muscle invasive bladder cancer
Meeks, J. J., Carneiro, B. A., Pai, S. G., Oberlin, D. T., RADEMAKER, A. W., Fedorchak, K., Balasubramanian, S., Elvin, J. A., Beaubier, N. T., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.12661 · Cited by 80
Xiao, W., Du, N., Huang, T., Guo, J., Mo, X., Yuan, T., Chen, Y., Ye, T., Xu, C., Wang, W., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.019 · Cited by 79
“In consistence with PFS, poorer OS was discovered in patients with TP53 mutation compared to patients with wild-type TP53 (median OS: 5.5 months vs. 9.6 months, P = 0.04, Fig.”
InfluentialDrakes, M. L., Mehrotra, S., Aldulescu, M., Potkul, R. K., Liu, Y., Grisoli, A., Joyce, C., O’Brien, T. E., Stack, M. S., & Stiff, P. J. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0414-z · Cited by 88
Qu, Y., Wen, J., Thomas, G., Yang, W., Prior, W., He, W., Sundar, P., Wang, X., Potluri, S., & Salek-Ardakani, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108115 · Cited by 76
Comprehensive assessment of cellular senescence in the tumor microenvironment
Wang, X., Ma, L., Pei, X., Wang, H., Tang, X., Pei, J.-F., Ding, Y.-N., Qu, S., Wei, Z.-Y., Wang, H.-Y., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac118 · Cited by 76
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer
Nersesian, S., Glazebrook, H. M., Toulany, J., Grantham, S. R., & Boudreau, J. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01782 · Cited by 90
“High mutational burdens have been associated with improved responses to immune checkpoint therapies in both melanoma and non-small cell lung cancers (102, 103).”
BackgroundDijkstra, K. K., Voabil, P., Schumacher, T. N., & Voest, E. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2214 · Cited by 75
Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy
Li, G., Mahajan, S., Ma, S., Jeffery, E. D., Zhang, X., Bhattacharjee, A., Venkatasubramanian, M., Weirauch, M. T., Miraldi, E. R., Grimes, H. L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ade2886 · Cited by 85
“To broadly assess the clinical relevance of splicing neoantigens in a large cancer cohort, we applied SNAF to more than 500 melanoma patient biopsies with (Van Allen cohort) ( 40 ) and without immuno-therapy (TCGA-SKCM) ( 41 ).”
MethodBassani-Sternberg, M., Digklia, A., Huber, F., Wagner, D., Sempoux, C., Stevenson, B. J., Thierry, A.-C., Michaux, J., Pak, H., Racle, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01832 · Cited by 74
Chae, Y. K., Anker, J. F., Oh, M. S., Bais, P., Namburi, S., Agte, S., Giles, F. J., & Chuang, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39594-4 · Cited by 79
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
Kato, S., Weng, Q. Y., Insco, M. L., Chen, K. Y., Muralidhar, S., Poźniak, J., Diaz, J. M. S., Drier, Y., Nguyen, N. T., Lo, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0532 · Cited by 79
“In another publicly available clinical melanoma dataset, higher G9a mRNA expression is significantly associated with worse response to anti-CTLA4 therapy (36) (Figure S10E).”
BackgroundTherapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 82
Wang, T.-Y., Liu, Q., Ren, Y., Alam, S. K., Wang, L., Zhu, Z., Hoeppner, L. H., Dehm, S. M., Cao, Q., & Yang, R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.028 · Cited by 82
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
de Velasco, G., Miao, D., Voss, M. H., Hakimi, A. A., Hsieh, J. J.-D., Tannir, N. M., Tamboli, P., Appleman, L. J., Rathmell, W. K., Allen, E. M. V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0110 · Cited by 81
“Clinical benefit from anti–CTLA-4 therapy is also associated with immunoreactive RNA-based signatures in the pretreatment tumor microenvironment (6).”
Self-citationOne microenvironment does not fit all: heterogeneity beyond cancer cells
Kim, I. S., & Zhang, X. H.-F. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9643-z · Cited by 79
“exhibited by anti-PD1, anti-PDL1, and anti-CTLA4 therapy [31–33], although the exact mechanism behind such success remains to be elucidated [34].”
BackgroundBethune, M. T., Li, X., Yu, J., McLaughlin, J., Cheng, D., Mathis, C., Moreno, B. H., Woods, K., Knights, A. J., García-Díaz, Á., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810653115 · Cited by 75
Chen, D., Chen, W., Xu, Y., Zhu, M., Xiao, Y., Shen, Y., Zhu, S., Cao, C., & Xu, X. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105454 · Cited by 75
RetractedCollins, J. M., Redman, J. M., & Gulley, J. L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506332 · Cited by 80
“response to ICI inmelanoma [66] and NSCLC [67].”
BackgroundBiomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1860586 · Cited by 80
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
Yang, L., Ning, Q., & Tang, S. (2022) · Journal of Immunology Research · doi:10.1155/2022/8052212 · Cited by 98
“Higher mutational load and neoantigen loads are significantly associated with the clinical benefit of anti-CTLA-4 antibodies [16].”
Voeller, J., Erbe, A. K., Slowinski, J., Rasmussen, K., Carlson, P. M., Hoefges, A., VandenHeuvel, S. N., Stuckwisch, A. M., Wang, X., Gillies, S. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0823-6 · Cited by 79
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
“the tumor microenvironment and the cancer mutational load.(64,67-74) However, the implementation of precision medi-”
BackgroundChen, M., Pockaj, B., Andreozzi, M., Barrett, M. T., Krishna, S., Eaton, S., Niu, R., & Anderson, K. S. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.05.006 · Cited by 71
Immune profiles in primary squamous cell carcinoma of the head and neck
Saloura, V., Izumchenko, E., Zuo, Z., Bao, R., Korzinkin, M., Ozerov, I. V., Zhavoronkov, A. A., Sidransky, D., Bedi, A., Hoque, M. O., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.032 · Cited by 74
“It has been reported that higher tumor mutational burden is associated with higher neoantigen load and durable clinical benefit in response to PD-1/PD-L1 checkpoint blockade, implying neoantigen-specific cytotoxic CD8+ T-cell infiltration in tumors with highly mutated genomes [22-24].”
BackgroundImmunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues
Şahin, İ. H., Ciombor, K. K., Diaz, L. A., Yu, J. B., & Kim, R. D. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349811 · Cited by 86
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
Jessurun, C. A. C., Vos, J. A. M., Limpens, J., & Luiten, R. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00233 · Cited by 81
“The studies of immune-related gene expression in tumor tissue, as described earlier, also included genes involved in T-cell activation and cytolytic activity, such as granzyme B or perforin (25, 64).”
BackgroundResultInfluentialNeoantigens encoded in the cancer genome
Schumacher, T. N., & Hacohen, N. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.07.005 · Cited by 80
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Wu, Z., Cui, P., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Chen, S., Huang, Z., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/1179554921996288 · Cited by 81
TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state
Matsuda, S., Revandkar, A., Dubash, T. D., Ravi, A., Wittner, B. S., Lin, M., Morris, R. T., Burr, R., Guo, H., Seeger, K., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112129 · Cited by 83
“69,70 In brief, RNA was extracted from FFPE specimens using the Qiagen AllPrep DNA/RNA Mini Kit (cat# 80204), followed by library preparation and sequencing using the TCap (Transcriptome Capture) protocol (genomics.broadinstitute.org/products/whole-transcriptome-sequencing).”
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 85
“Subsequently, the creators of IMPRES have validated the score using an independent melanoma dataset 56 and suggested that differences resulted from processing of the RNA-seq data 298 .”
InfluentialQin, A., Coffey, D. G., Warren, E. H., & Ramnath, N. (2016) · Cancer Medicine · doi:10.1002/cam4.819 · Cited by 80
“found higher PFS and OS in patients with cancers harboring DNA mismatch-repair deficiency when treated with pembrolizumab compared to those with tumors that were mismatch-repair proficient.(56) Mismatch-repair deficient tumors expressed a mean of 1782 somatic mutations per tumor compared to 73 mutations per tumor in m…”
ResultGarg, A. D., Vandenberk, L., Van Woensel, M., Belmans, J., Schaaf, M., Boon, L., De Vleeschouwer, S., & Agostinis, P. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1295903 · Cited by 71
“, non-synonymous somatic single-nucleotide variations).(19,20) In fact,”
Varn, F. S., Tafe, L. J., Amos, C. I., & Cheng, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431084 · Cited by 72
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Garinet, S., Laurent‐Puig, P., Blons, H., & Oudart, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060144 · Cited by 75
Lin, B., Liu, J., Wang, Y., Yang, F., Huang, L., & Lv, R. (2020) · Chemistry of Materials · doi:10.1021/acs.chemmater.0c01031 · Cited by 70
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Bartolomeo, M. D., Mandalà, M., Ryu, M.-H., Caglevic, C., Chung, H. C., Muro, K., Cutsem, E. V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.803 · Cited by 78
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy
Maggs, L., Sadagopan, A., Moghaddam, A. S., & Ferrone, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.07.006 · Cited by 79
Levi, S. T., Copeland, A. R., Nah, S., Crystal, J. S., Ivey, G. D., Lalani, A., Jafferji, M. S., White, B. S., Parikh, N. B., Leko, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4499 · Cited by 75
Zhang, N., Zhang, H., Liu, Z., Dai, Z., Wu, W., Zhou, R., Li, S., Wang, Z., Liang, X., Wen, J., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13409 · Cited by 81
Scolaro, T., Manco, M., Pecqueux, M., Amorim, R., Trotta, R., Acker, H. H. V., Haele, M. V., Shirgaonkar, N., Naulaerts, S., Daniluk, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00771-8 · Cited by 83
“Despite the high response rates with prolonged survival in subsets of individuals with melanoma 3 , lung 4 and renal cancer 5 , ICB failed to show clinical benefit in several other tumors, such as the majority of mismatch repair-proficient colorectal cancers 6 and pancreatic ductal adenocarcinoma…”
Chhabra, Y., Fane, M. E., Pramod, S., Hüser, L., Zabransky, D. J., Wang, V., Dixit, A., Zhao, R., Kumah, E., Brezka, M. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.013 · Cited by 77
Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers
Inthagard, J., Edwards, J., & Roseweir, A. K. (2019) · Clinical Science · doi:10.1042/cs20181003 · Cited by 77
Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy
Fenizia, F., Pasquale, R., Roma, C., Bergantino, F., Iannaccone, A., & Normanno, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.23 · Cited by 69
“TMB has newly emerged as a possible independent biomarker to predict patient responses to immunotherapy in different tumor types, including lung cancer (2,3,15-22).”
BackgroundMethodRole of DNA repair defects in predicting immunotherapy response
Zhang, J., Shih, D. J. H., & Lin, S.-Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00202-7 · Cited by 69
Schaettler, M. O., Richters, M. M., Wang, A. Z., Skidmore, Z. L., Fisk, B., Miller, K. E., Vickery, T. L., Kim, A. H., Chicoine, M. R., Osbun, J. W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0291 · Cited by 69
Gao, Y., Wang, H., Chen, S., An, R., Chu, Y., Li, G., Wang, Y., Xie, X., & Zhang, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03395-7 · Cited by 80
“(2017, anti-PD1, Melanoma [28]); VanAllen (2016, CTLA4, MetMelanoma [29])), and other 4 non-melanoma cohorts (IMvigor210 (2018, anti-PDL1,Urothelial Cancer [30]); Braun et al.”
BackgroundPulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 74
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Takazawa, M., Ohara, O., et al. (2016) · Cancer Science · doi:10.1111/cas.13131 · Cited by 71
CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens
Bais, P., Namburi, S., Gatti, D. M., Zhang, X., & Chuang, J. H. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx375 · Cited by 69
Waalkes, A., Smith, N. T., Penewit, K. M., Hempelmann, J. A., Konnick, E. Q., Hause, R. J., Pritchard, C. C., & Salipante, S. J. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.285981 · Cited by 77
Kreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 80
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 71
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 78
“High neoantigen load was generally correlated with high TMB, providing a rationale for using TMB as a predictor of immunotherapy response across different cancers [22,183].”
BackgroundNavigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
Zhang, J., Caruso, F. P., Sa, J. K., Justesen, S. F. L., Nam, D., Sims, P. A., Ceccarelli, M., Lasorella, A., & Iavarone, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0369-7 · Cited by 72
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
Simeone, E., Grimaldi, A. M., Festino, L., Vanella, V., Palla, M., & Ascierto, P. A. (2017) · BioDrugs · doi:10.1007/s40259-016-0208-z · Cited by 71
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
van Wilpe, S., Tolmeijer, S. H., Koornstra, R. H. T., de Vries, I. J. M., Gerritsen, W. R., Ligtenberg, M. J. L., & Mehra, N. (2021) · Cancers · doi:10.3390/cancers13092249 · Cited by 77
“Across cancer types, only 89% of patients with a germline BRCA1 variant and 79% of patients with a BRCA2 variant have a tumor with complete loss of the wildtype allele [30].”
BackgroundInfluentialZhu, G., Shi, R., Li, Y., Zhang, Z., Xu, S., Chen, C., Cao, P., Zhang, H., Liu, M., Pan, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670040 · Cited by 69
Oncogenic CDK13 mutations impede nuclear RNA surveillance
Insco, M. L., Abraham, B. J., Dubbury, S. J., Kaltheuner, I. H., Dust, S., Wu, C., Chen, K. Y., Liu, D., Bellaousov, S., Cox, A. M., et al. (2023) · Science · doi:10.1126/science.abn7625 · Cited by 72
Self-citationVáraljai, R., Zimmer, L., Al-Matary, Y. S., Kaptein, P., Albrecht, L. J., Shannan, B., Brase, J. C., Gusenleitner, D., Amaral, T. M. S., Wyss, N., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00610-2 · Cited by 75
“Raw gene expression counts from the Van Allen et al. 16 study were normalized using the DESeq2 version 3.17.”
InfluentialSelf-citationThe Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis
Wei, Z., Zhou, C., Zhang, Z., Guan, M., Zhang, C., Liu, Z., & Liu, Q. (2019) · iScience · doi:10.1016/j.isci.2019.10.028 · Cited by 67
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
Vanni, I., Tanda, E. T., Spagnolo, F., Andreotti, V., Bruno, W., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00113 · Cited by 72
Tripathi, R., Modur, V., Senovilla, L., Kroemer, G., & Komurov, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657374 · Cited by 68
“As such, tumor mutational load was found to correlate with TLI in a panel of cancers,(8) as well as with the clinical response to PD1 and CTLA4 blockade in lung cancer and melanoma patients.(5,7,9,10) A recent study found a strong negative correlation of TLI with tumor aneuploidy, meaning that highly aneuploid tumors…”
Lü, Z., Chen, H., Li, S., Gong, J., Li, J., Zou, J., Wu, L., Yu, J., Han, W., Sun, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000374 · Cited by 71
Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 74
“They were inspired by a study from Van Allen and collaborators whereby melanoma samples with high numbers of alterations had more chances to respond to immunotherapy due to increased odds of immunogenic neoantigens produced by tumor cells [100].”
BackgroundIdentification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
Long, J., Wang, D., Yang, X., Wang, A., Lin, Y. S., Zheng, M., Zhang, H., Sang, X., Wang, H., Hu, K., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02031-3 · Cited by 67
Metadata
- Authors
- Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., Utikal, J., Hassel, J. C., Weide, B., Kaehler, K. C., Loquai, C., Mohr, P., Gutzmer, R., Dummer, R., Gabriel, S., Wu, C. J., Schadendorf, D., & Garraway, L. A.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- The Netherlands Cancer Institute (NL)
- Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
- University Hospital Zurich (CH)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Universitätsklinikum Tübingen (DE)
- University Hospital Schleswig-Holstein (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Miao, Diana
- Schilling, Bastian
- Schadendorf, Dirk
- Garraway, Levi A.
- ORCID
- Venue
- Science
- Published
- 2015-10-09
- Volume
- 350
- Issue
- 6257
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5054517
- OpenAlex
- W2107429737
- Cited by
- 2,839
- References
- 42
- Citations by year
- 2026: 106 · 2025: 187 · 2024: 236 · 2023: 308 · 2022: 313 · 2021: 348 · 2020: 327 · 2019: 274 · 2018: 270 · 2017: 248 · 2016: 207 · 2015: 12
- FWCI
- 107.45
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- NIH (U54 HG003067)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, CTLA-4 blockade, ipilimumab, immune checkpoint inhibitors, tumor mutational burden, neoantigens, tumor microenvironment, predictive biomarkers, treatment response, exome sequencing, transcriptome, germline mutations
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antigens, Neoplasm, DNA Mutational Analysis, Female, HLA Antigens, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Cohort Studies, Drug Resistance, Neoplasm, Genomics, Biomarkers, Pharmacological, Young Adult, Tumor Microenvironment, Cell Cycle Checkpoints, Exome, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.